Immunotherapy Boost for Bile Duct Cancer Survival Holds Firm After Three Years
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
The Phase III NRG-GI003 trial was stopped early for futility after proton therapy failed to improve overall survival compared with ...
A Phase III NRG Oncology trial found that stereotactic radiosurgery did not improve neurocognitive outcomes over hippocampal-avoidant whole-brain radiotherapy but ...
A Mayo Clinic-led randomized trial found that delivering postoperative stereotactic radiosurgery in three or five fractions instead of one reduced ...
A meta-analysis of 41 studies and 3,058 patients shows that detectable circulating tumor DNA after neoadjuvant therapy strongly predicts worse ...
A new study finds that an elevated platelet-to-lymphocyte ratio from a routine blood count strongly predicts poorer survival in relapsed ...
A first-in-human trial shows that the conformation-selective PI3Kδ inhibitor roginolisib is well tolerated in advanced cancers and is associated with ...
A real-world study of 178 esophageal cancer patients shows that residual tumor grade and post-treatment lymph node status, especially ypN3, ...
A multicenter study shows that a hybrid model combining MRI radiomics, delta features, and clinical variables predicts overall survival in ...
A meta-analysis of 17 studies finds that Helicobacter pylori infection is associated with worse overall and progression-free survival in cancer ...
© 2026 Scienmag - Science Magazine
© 2026 Scienmag - Science Magazine